PURE AND MIXED CLEAR CELL CARCINOMA 85 4 Deceased Yes 15 (35) 11 (50) 4 (19) 0.033 No 28 (65) 11 (50) 17 (81) Deceased EC-related 0.065 Yes 14 (33) 10 (46) 4 (19) No 29 (67) 12 (55) 17 (81) P-values were obtained using the Mann-Whitney U test, Fisher’s exact test and χ². Values are presented as median (range) or number (%). BMI, body mass index; CA-125, cancer antigen 125; EC, endometrial cancer. * excluding patients with residual disease Table 2. Immunohistochemical staining Pure Mixed Clear cell component Other component Estrogen receptor Positive Negative 5 (24) 16 (76) 11 (52) 10 (48) 21 (100) 0 Progesterone receptor Positive Negative 1 (5) 21 (96) 6 (29) 15 (71) 16 (84) 3 (16)* L1CAM Negative Positive 5 (23) 17 (77) 6 (29) 15 (71) 16 (76) 5 (24) PMS2 Positive Negative 22 (100) 0 20 (95) 1 (5) 20 (95) 1 (5) MSH6 Positive Negative 21 (95) 1 (5) 14 (67) 7 (33) 14 (67) 7 (33) * Not assessable in 2 cases. L1CAM, L1 cell adhesion molecule. Molecular patterns Of 43 patients, 8 were excluded for analyses due to either poor quality DNA and/or failed sequencing, leaving 35 patients for analysis. In one patient with mixed uterine CCC/serous carcinoma, a POLE hotspot mutation (c.857C>G) was found (both components could not be separately extracted, Table 3). Within the pure uterine CCCs, one patient had a tumor with MSI (5%), while 9 patients (43%) with mixed uterine CCC (p=0.004) showed MSI. In 7 patients (41%) with pure uterine CCC, a TP53 mutation was found, which was also the case for the mixed uterine CCCs (39%). Within the TP53 mutated cases, MSI was present in Table 1. Continued
RkJQdWJsaXNoZXIy MTk4NDMw